Mark D. Minden
A5026397928- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- RNA Interference and Gene Delivery
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Retinoids in leukemia and cellular processes
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Neutropenia and Cancer Infections
- RNA Research and Splicing
- Cytokine Signaling Pathways and Interactions
- Cancer, Hypoxia, and Metabolism
- Immune cells in cancer
- Advanced biosensing and bioanalysis techniques
- Lymphoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
Princess Margaret Cancer Centre
2016-2025
University Health Network
2016-2025
University of Toronto
2016-2025
Ontario Institute for Cancer Research
2014-2024
Health Net
2013-2023
Research Canada
2022
Cancer Institute (WIA)
1988-2021
Montreal Clinical Research Institute
2021
Université de Montréal
2021
Toronto Public Health
2021
This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients newly diagnosed acute myeloid leukemia (AML) poor- or intermediate-risk cytogenetics.Patients (N = 485) age ≥ 65 years were randomly assigned 1:1 to receive 20 mg/m(2) per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks TC (supportive care cytarabine subcutaneous injection 10 weeks). The primary end point was...
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present most gliomas secondary glioblastomas, but rare other neoplasms. IDH1/2 mutations heterozygous, affect a single arginine residue. Recently, IDH1 were identified 8% of acute myelogenous leukemia (AML) patients. A glioma study revealed that cause gain-of-function, resulting the production accumulation 2-hydroxyglutarate (2-HG). Genotyping 145 AML biopsies 11 R132 mutant samples. Liquid chromatography-mass spectrometry...
Molecular cloning of the t(10;14)(q24;q11) recurrent breakpoint T cell acute lymphoblastic leukemia has demonstrated a transcript for candidate gene TCL3. Characterization this from chromosome segment 10q24 revealed it to be new homeobox, HOX11. The HOX11 homeodomain is most similar that murine Hlx and possesses markedly glycine-rich variable region an acidic carboxyl terminus. HOX11, while expressed in liver, was not detected normal thymus or cells. This lineage-restricted homeobox...
Purpose Philadelphia chromosome (Ph) –like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors. We sought define the prevalence and genomic landscape Ph-like in adults assess response conventional chemotherapy. Patients Methods The frequency was assessed gene expression profiling 798 patients B-cell age 21 86 years. Event-free survival overall were determined...
The mitochondrial caseinolytic protease P (ClpP) plays a central role in protein quality control by degrading misfolded proteins. Using genetic and chemical approaches, we showed that hyperactivation of the selectively kills cancer cells, independently p53 status, selective degradation its respiratory chain substrates disrupts structure function, while it does not affect non-malignant cells. We identified imipridones as potent activators ClpP. Through biochemical studies crystallography,...
Abstract Chromosomal rearrangements are initiating events in acute lymphoblastic leukaemia (ALL). Here using RNA sequencing of 560 ALL cases, we identify between MEF2D (myocyte enhancer factor 2D) and five genes ( BCL9 , CSF1R DAZAP1 HNRNPUL1 SS18 ) 22 B progenitor (B-ALL) cases with a distinct gene expression profile, the most common which is MEF2D-BCL9 . Examination an extended cohort 1,164 B-ALL identified 30 rearrangements, include additional fusion partner, FOXJ2 ; thus, MEF2D-...
To investigate miRNA function in human acute myeloid leukemia (AML) stem cells (LSC), we generated a prognostic LSC-associated signature derived from functionally validated subpopulations of AML samples. For one miRNA, miR-126, high bioactivity aggregated all vivo patient sample LSC activity into single sorted population, tightly coupling miR-126 expression to function. Through functional studies, was found restrain cell cycle progression, prevent differentiation, and increase self-renewal...